CD40 and inflammatory bowel disease: In mouse models of chronic colitis, CD40L antagonism blocks IL-12 production, pathogenic Th1 response, and consequent inflammation, highlighting the promise of CD40/CD40L blockade in IBD (De Jong et al., 2000; Stuber et al., 1996).